- Home
- ZENV vs SLS Comparison
ZENV vs SLS Comparison
Compare ZENV & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- SLS
- Stock Information
- Founded
- ZENV 2005
- SLS 2012
- Country
- ZENV Brazil
- SLS United States
- Employees
- ZENV N/A
- SLS N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- SLS Health Care
- Exchange
- ZENV Nasdaq
- SLS Nasdaq
- Market Cap
- ZENV 63.3M
- SLS 75.3M
- IPO Year
- ZENV 2021
- SLS N/A
- Fundamental
- Price
- ZENV $1.62
- SLS $0.89
- Analyst Decision
- ZENV
- SLS
- Analyst Count
- ZENV 0
- SLS 0
- Target Price
- ZENV N/A
- SLS N/A
- AVG Volume (30 Days)
- ZENV 73.5K
- SLS 1.7M
- Earning Date
- ZENV 11-18-2024
- SLS 11-13-2024
- Dividend Yield
- ZENV N/A
- SLS N/A
- EPS Growth
- ZENV N/A
- SLS N/A
- EPS
- ZENV N/A
- SLS N/A
- Revenue
- ZENV $173,594,726.00
- SLS N/A
- Revenue This Year
- ZENV $25.56
- SLS N/A
- Revenue Next Year
- ZENV $6.02
- SLS N/A
- P/E Ratio
- ZENV N/A
- SLS N/A
- Revenue Growth
- ZENV 23.49
- SLS N/A
- 52 Week Low
- ZENV $1.00
- SLS $0.50
- 52 Week High
- ZENV $3.88
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- ZENV 54.93
- SLS 34.98
- Support Level
- ZENV $1.61
- SLS $0.83
- Resistance Level
- ZENV $1.78
- SLS $0.98
- Average True Range (ATR)
- ZENV 0.12
- SLS 0.11
- MACD
- ZENV -0.00
- SLS -0.02
- Stochastic Oscillator
- ZENV 48.48
- SLS 25.65
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.